ECDB-Endometrial cancer gene database

REFERENCES

Gene Name	Gene ID	Pubmed ID	Classification	Mechanism	Marker	Type	Normal Cases	Disease Cases	Age	Mean Age	Place	FIGO	Grade	Remark	Title	Journal	Volume	Year
IGF2	3481	15066926	-	-	-	-	136	174	-	-	Chicago (Northwestern University); IL; Chicago (Rush Medical College); IL; Hershey; PA; Irvine; CA; Long Beach; CA; Minneapolis; MN; and Winston-Salem; NC	-	-	[1] Serum IGF-2 is inversely associated with endometrial cancer in postmenopausal women. These associations and the potential role of the IGF system in endometrial proliferation and carcinogenesis warrant further research. [2] Endometrial cancer was inversely associated with IGF-2 (OR for the highest tertile = 0.35; 95% CI = 0.18-0.69) and IGFBP-3 (OR for the highest tertile = 0.40; 95% CI = 0.21-0.77).	Insulin-like growth factors; insulin-like growth factor-binding proteins; and endometrial cancer in postmenopausal women: results from a U.S. case-control study	Cancer epidemiology; biomarkers & prevention	13(4):607-12	2004
IGF2	3481	15930340	-	Differentially expressed		-	-	119 (66 endometrioid; 24 papillary serous; 29 mixed mullerian tumors)	-	-	Duke University Medical Centre; North Carolina	-	-	[1] The microarray study shows that this gene is differently expressed in endometrioid carcinoma profile; reflecting expression value 0.259 and 0.104 on both the endometrioid versus papillary serous carcionma and endometrioid versus mixed mullerian tumor respectively. [2] IGF2 was noted to be overexpressed in the analysis of mixedmullerian tumors (P < 0.001) when compared with bothendometrioid and papillary serous endometrial cancers. [3] associated with a >2-fold papillary serous/endometrioid expression ratio.	Microarray analysis of endometrial carcinomas and mixed mullerian tumors reveals distinct gene expression profiles associated with different histologic types of uterine cancer	Clinical Cancer Research	11(11):4056-66	2005